Cover Image

Disconnect between signalling potency and in vivo efficacy of pharmacokinetically optimised biased glucagon-like peptide-1 receptor agonists

Objective: The objective of this study was to determine how pharmacokinetically advantageous acylation impacts on glucagon-like peptide-1 receptor (GLP-1R) signal bias, trafficking, anti-hyperglycaemic efficacy, and appetite suppression. Methods: In vitro signalling responses were measured using bio...

Full description

Saved in:

Bibliographic Details
Main Authors:	Maria Lucey (Author), Philip Pickford (Author), Stavroula Bitsi (Author), James Minnion (Author), Jan Ungewiss (Author), Katja Schoeneberg (Author), Guy A. Rutter (Author), Stephen R. Bloom (Author), Alejandra Tomas (Author), Ben Jones (Author)
Format:	Book
Published:	Elsevier, 2020-07-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Partial agonism improves the anti-hyperglycaemic efficacy of an oxyntomodulin-derived GLP-1R/GCGR co-agonist
by: Phil Pickford, et al.
Published: (2021)

Investigating the Glucagon Receptor and Glucagon-Like Peptide 1 Receptor Activity of Oxyntomodulin-Like Analogues in Male Wistar Rats
by: Samantha L. Price, MRes, et al.
Published: (2015)

Receptor Activity-Modifying Protein 2 (RAMP2) alters glucagon receptor trafficking in hepatocytes with functional effects on receptor signalling
by: Emma Rose McGlone, et al.
Published: (2021)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
by: Seungah Lee, et al.
Published: (2017)

Glucagon-like peptide-1 (GLP-1) agonists in the treatment of obesity
by: Magdalena Mazurek, et al.
Published: (2023)

Agonist bias and agonist‐dependent antagonism at corticotrophin releasing factor receptors
by: Zoe Tasma, et al.
Published: (2020)

Healthcare professionals' perceptions and management of obesity & knowledge of glucagon, GLP‐1, GIP receptor agonists, and dual agonists
by: W. Timothy Garvey, et al.
Published: (2024)

Hepatocyte cholesterol content modulates glucagon receptor signalling
by: Emma Rose McGlone, et al.
Published: (2022)

Pharmacoeconomic characteristics of agonists of receptors for glucagon-like peptide-1 and medicines on their base
by: I. N. Dyakov, et al.
Published: (2021)

Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease
by: Laurie L. Baggio, et al.
Published: (2021)

Glucagon-like peptide-1 receptor agonists and derivatives in the treatment of obesity - review
by: Michal Rabenda, et al.
Published: (2024)

Intimate Disconnections Divorce and the Romance of Independence in Contemporary Japan
by: Alexy, Allison
Published: (2020)

Intimate Disconnections Divorce and the Romance of Independence in Contemporary Japan
by: Alexy, Allison
Published: (2020)

Effect of Glucagon-like peptide-1 receptor agonists on dyslipidemia in type 2 diabetes
by: Elizabeth A. Cristiano, et al.
Published: (2020)

Impact of Glucagon-like Peptide-1 Receptor Agonists on Intestinal Epithelial Cell Barrier
by: Takizawa Y., et al.
Published: (2024)

The Therapeutic Potential of Glucagon-like Peptide 1 Receptor Agonists in Traumatic Brain Injury
by: Anja Harej Hrkać, et al.
Published: (2024)

Amelioration of muscle wasting by glucagon‐like peptide‐1 receptor agonist in muscle atrophy
by: Yeonhee Hong, et al.
Published: (2019)

ADHD and Frontal-Motor Cortex Disconnection
by: J Gordon Millichap
Published: (1997)

Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus
by: Olusola F. Onoviran, et al.
Published: (2019)

Glucagon-like peptide-1 receptor agonists for treatment of diabetes and obesity: advantage of oral delivery
by: R. R. C. New, et al.
Published: (2024)

Reconnect or disconnect - Truth is stranger than fiction
by: Harpreet Singh Grover
Published: (2022)

Speaking of sadness: depression, disconnection and the meaning of illness
by: Nicholas Procter
Published: (1997)

Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease-Current Evidence
by: Emir M. Muzurović MD, MM, et al.
Published: (2022)

Economic analysis of glucagon like peptide-1 receptor agonists from the Saudi Arabia payer perspective
by: Nimer S. Alkhatib, et al.
Published: (2022)

Glucagon-like peptide-1 receptor agonists as add-on therapy to insulin for type 1 diabetes mellitus
by: Xinrui Tan, et al.
Published: (2023)

Possible Mechanisms Underlying the Effects of Glucagon-Like Peptide-1 Receptor Agonist on Cocaine Use Disorder
by: Changliang Zhu, et al.
Published: (2022)

Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations
by: Dan Xu, et al.
Published: (2022)

The economic side of an oral sugar lowering therapy intensification by glucagon-like peptidt-1 receptor agonists
by: S. K. Zyryanov, et al.
Published: (2022)

The Impact of Glucagon-like Peptide 1 Receptor Agonists on Obstructive Sleep Apnoea: A Scoping Review
by: Khang Duy Ricky Le, et al.
Published: (2024)

Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
by: Patrick J. Knerr, et al.
Published: (2022)

Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: A review of their kidney and heart protection
by: Erin D. Michos, et al.
Published: (2023)

The Role of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) in Diabetes-Related Neurodegenerative Diseases
by: Cheng D, et al.
Published: (2022)

Glucagon-like peptide-1 receptor agonists: new strategies and therapeutic targets to treat atherosclerotic cardiovascular disease
by: Tianyu Wang, et al.
Published: (2024)

Clinical Impact of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist, on Obesity Management: A Review
by: Alorfi NM, et al.
Published: (2022)

The Impact of Glucagon-Like Peptide 1 Receptor Agonists on Bone Metabolism and Its Possible Mechanisms in Osteoporosis Treatment
by: Baocheng Xie, et al.
Published: (2021)

Amelioration of inflammatory myopathies by glucagon‐like peptide‐1 receptor agonist via suppressing muscle fibre necroptosis
by: Mari Kamiya, et al.
Published: (2022)

A Comprehensive Review on Weight Gain following Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists for Obesity
by: Ibrahim Abdullah bin Ahmed
Published: (2024)

Dietary protein defends lean mass and maintains the metabolic benefits of glucagon receptor agonism in mice
by: Tatiana Lopes, et al.
Published: (2024)

Discovery of ecnoglutide - A novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog
by: Wanjun Guo, et al.
Published: (2023)

OVERCOMING THE DISCONNECTION BETWEEN SOCIO-PEDAGOGICAL PRACTICE AND LAW
by: Marina P. Guriyanova, et al.
Published: (2015)